Histological and biochemical studies on effect of Sofosbuvir (Sovaldi) on adult male albino rat kidney
- 16 August 2021
- journal article
- research article
- Published by Taylor & Francis in Ultrastructural Pathology
- Vol. 45 (4-5) , 286-296
Abstract
Sofosbuvir (sovaldi) is the backbone of many anti‐HCV drugs. We aimed to demonstrate the effect of sofosbuvir on the adult male albino rat kidney. Sixty adult male albino rats were used. The animals were divided equally into 2 main groups (I and II), and each group was divided equally into 3 subgroups (A, B, and C). In group I (control group), each rat was gavaged 0.5 ml distilled water daily for 4 weeks. In group II (sofosbuvir treated group), each albino rat was gavaged 0.5 ml distilled water containing 7.2 mg sofosbuvir daily for 4 weeks. The rats were sacrificed at the end of the 4th week (subgroups IA and IIA), 6th week (subgroups IB and IIB), and 8th week (subgroups IC and IIC) from the start of the treatment. The kidneys were used for histological study while blood samples were used for biochemical study. The obtained data were statistically analyzed. Sofosbuvir (sovaldi) induced pathological changes that gave the criteria of acute Kidney injury in the adult male albino rats. The pathological changes were confirmed by elevation of serum level of urea and creatinine. After 2 and 4 weeks of drug withdrawal, the kidney incompletely recovered. We concluded that sofosbuvir induced criteria of acute tubular injury in the kidney of the adult male albino rats. This renal injury was proved by histological and biochemical studies. These insults were incompletely reversible after the end the treatment.Keywords
Funding Information
- funded
This publication has 19 references indexed in Scilit:
- Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal functionLiver International, 2016
- Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C VirusAntimicrobial Agents and Chemotherapy, 2016
- Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case seriesPostgraduate Medicine, 2015
- Sofosbuvir: A novel treatment option for chronic hepatitis C infectionJournal of Pharmacology and Pharmacotherapeutics, 2014
- Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potentialTherapeutic Advances in Gastroenterology, 2013
- A Novel Promising Therapeutic Option Against Hepatitis C Virus: An Oral Nucleotide NS5B Polymerase Inhibitor SofosbuvirCurrent Medicinal Chemistry, 2013
- Tenofovir renal toxicity targets mitochondria of renal proximal tubulesLaboratory Investigation, 2009
- Antiviral Drug-Induced NephrotoxicityAmerican Journal of Kidney Diseases, 2005
- A mouse model of severe acute pancreatitis induced with caerulein and lipopolysaccharideWorld Journal of Gastroenterology, 2003
- The nature of renal cell injuryKidney International, 1997